샘플 요청 목록

 카트 문의
시장보고서
상품코드
1584097

타미플루 시장 : 제형별, 약제 유형별, 적응증별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Tamiflu Market, By Dosage Form, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 322 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

타미플루 시장 규모는 2023년에 19억 2,032만 달러에 달하며, 2024-2032년 CAGR 3.40%로 확대

타미플루 시장 - 시장 역학

세계의 계절성 인플루엔자의 진보와 COVID-19 팬데믹시의 수요 증가가 시장 수요를 촉진

타미플루(오셀타미비르 인산염)는 항바이러스제로 생후 2주 이상된 생후 2주 이내에 독감 증상이 나타난 환자를 대상으로 급성, 무증상 인플루엔자 A형 및 B형, 돼지 인플루엔자(H1N1)의 치료에 적응증을 가지고 있습니다. 캡슐과 경구용 현탁액 두 가지 유형이 있습니다. 타미플루(오셀타미비르 인산염) 시장은 비교적 가벼운 부작용으로 인해 전 세계 계절성 독감 유행 증가와 COVID-19 팬데믹 기간 중 수요 증가에 힘입어 예측 기간 중 성장할 것으로 예상됩니다. 또한 많은 제약사들이 오셀타미비르 인산염의 제네릭 의약품을 출시하고 있는 것도 시장 확대에 박차를 가할 것으로 예상됩니다. 타미플루는 A형, B형, 돼지 인플루엔자 치료에 적응증을 가지고 있으므로 전 세계 인플루엔자 환자 증가는 시장을 촉진할 것으로 예상됩니다. 예를 들어 세계보건기구(WHO)의 2021년 11월 보고서에 따르면 2020년 전 세계에서 300만-500만 명의 중증 독감 환자가 발생했다고 합니다.

Tamiflu 시장 - 주요 인사이트

당사의 리서치 애널리스트들이 공유한 분석에 따르면 세계 시장은 예측 기간(2024-2032년) 동안 연평균 약 3.40%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 추정됩니다.

약물 유형별로는 제네릭 의약품이 22023년 가장 높은 시장 점유율을 차지했습니다.

제형별로는 2023년 캡슐이 주요 유형으로 부상할 것으로 예상됩니다.

지역별로는 북미가 2023년 매출 1위

타미플루 시장 - 세분화 분석 :

타미플루 세계 시장은 제형, 약물 유형, 적응증, 유통 채널, 지역별로 구분됩니다.

약물의 유형에 따라 시장은 오리지널 의약품과 제네릭 의약품의 두 가지로 분류됩니다. 제네릭 의약품은 계절성 독감 치료에서 오셀타미비르 인산염에 대한 높은 수요에 힘입어 예측 기간 중 시장을 지배할 것으로 예상됩니다. 타미플루의 제네릭은 보다 비용 효율적인 솔루션으로 다양한 환자와 의료 시스템에서 쉽게 이용할 수 있습니다. 이러한 저렴한 가격과 오리지널 의약품과 동등한 효능은 특히 비용에 민감한 의료 모델을 가진 지역에서 제네릭 의약품을 선호하는 요인으로 작용하고 있습니다. 또한 타미플루의 특허가 만료된 후 많은 제약회사들이 제네릭 의약품을 출시하면서 시장 경쟁이 치열해져 가격이 더욱 낮아지고 접근성이 높아졌습니다.

시장은 제형에 따라 캡슐과 현탁액으로 나뉩니다. 캡슐은 독감 치료에 널리 사용되므로 예측 기간 중 시장을 주도할 것으로 예상됩니다. 캡슐은 편리하고 투여가 용이하며 합병증 없이 독감 치료에 있으며, 환자와 의료 서비스 프로바이더가 선호하고 있습니다. 또한 캡슐은 현탁액에 비해 안정성이 높고 보존 기간이 길어 비축 및 유통에 적합합니다. 반면 경구용 현탁액은 일반적으로 유아나 특정 질환을 앓고 있는 환자 등 캡슐을 삼킬 수 없는 환자에게만 사용됩니다. 타미플루는 이러한 사람들의 접근성을 보장하는 데 중요한 역할을 하지만, 경구용 현탁액에 대한 수요는 여전히 캡슐에 비해 낮으며 후자 시장 우위가 강화되고 있습니다.

타미플루 시장 - 지역적 인사이트

예측 기간 중 북미가 타미플루 시장을 독점할 것으로 예상되는데, 그 주요 이유는 시장 점유율이 높고 향후 독감 시즌을 대비한 타미플루 비축량이 증가하고 있기 때문입니다. 예를 들어 미국 정부는 2022년 12월 21일 미국 보건복지부(HHS)가 전략적 준비 및 대응국(ASPR)과 함께 2022년 독감 시즌 동안 수요 증가에 대응하기 위해 타미플루를 추가 비축할 것이라고 발표했습니다. 이는 전략적 국가비축(SNS)을 통해 이루어졌습니다. 정부는 ASPR 지역팀과 협력하여 SNS의 타미플루 배포 요청을 평가하여 주, 준주 및 부족이 필요한 지원을 받을 수 있도록 하는 한편, 향후 신종 인플루엔자 발생에 대비할 수 있도록할 것입니다.

타미플루 시장 - 경쟁 구도:

타미플루 시장의 업체들은 경쟁력을 높이고 시장 점유율을 확대하기 위해 다양한 전략을 시행하고 있습니다. 여기에는 독감 예방과 치료에 대한 의료진과 일반 대중의 인식을 높이기 위한 강력한 마케팅 캠페인이 포함됩니다. 기업은 또한 정부 및 보건 기관과의 파트너십을 우선순위에 두고 독감 유행 기간 및 대유행시 항바이러스제 비축을 위한 계약을 체결하고 있습니다. 연구개발 노력도 중요하며, 신종 플루에 대응할 수 있는 차세대 항바이러스 치료제를 개발하는 데 중점을 두고 투자하고 있습니다. 또한 가격 전략은 의료 시스템의 예산에 맞게 설계되어 필요한 환자에게 폭넓은 접근성을 보장하는 동시에 의료 시스템의 예산에 맞게 설계되어 있습니다.

목차

제1장 타미플루 시장 개요

  • 조사 범위
  • 시장 추정년

제2장 개요

  • 시장 내역
  • 경쟁 인사이트

제3장 타미플루의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장의 향후 동향

제4장 타미플루 업계의 연구

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 지도제작
  • 규제 구조 분석

제5장 타미플루 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 타미플루 시장 구도

  • 타미플루 시장 점유율 분석, 2023년
  • 주요 제조업체별 내역 데이터
    • 기존 기업의 분석
    • 신규 기업의 분석

제7장 타미플루 시장 - 제형별

  • 개요
    • 제형별 부문 점유율 분석
    • 캡슐
    • 현탁제

제8장 타미플루 시장 - 약제 유형별

  • 개요
    • 약제 유형별 부문 점유율 분석
    • 브랜드
    • 제네릭

제9장 타미플루 시장 - 적응증별

  • 개요
    • 적응증별 부문 점유율 분석
    • 인플루엔자 A
    • 인플루엔자 B
    • 돼지 인플루엔자(H1N1 인플루엔자 A)

제10장 타미플루 시장 - 유통 채널별

  • 개요
    • 유통 채널별 부문 점유율 분석
    • 병원 약국
    • 소매 약국
    • 온라인 약국

제11장 타미플루 시장 - 지역별

  • 서론
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제12장 주요 벤더 분석 - 타미플루 업계

  • 경쟁 대시보드
  • 기업 개요
    • F. Hoffmann-La Roche Ltd.
    • NATCO Pharma Limited
    • Teva Pharmaceutical Industries Ltd
    • LUPIN Limited
    • Amneal pharmaceuticals LLC
    • Zydus Cadila
    • Sun Pharmaceutical Industries Ltd.
    • Alembic Pharmaceuticals Limited
    • Mylan NV
    • Hetero Group
    • Others

제13장 애널리스트의 전방위 전망

KSA 24.11.14

REPORT HIGHLIGHT

Tamiflu Market size was valued at USD 1,920.32 Million in 2023, expanding at a CAGR of 3.40% from 2024 to 2032.

Tamiflu, also known as oseltamivir, is an antiviral medication commonly used to treat and prevent influenza infections. It works by inhibiting neuraminidase enzyme, which the virus needs to spread within the respiratory system. Tamiflu is most effective in reducing flu symptoms' duration and severity when taken within the first 48 hours of symptom onset. It can also be prescribed as a preventive measure for individuals at high risk of complications from the flu. Due to its effectiveness, Tamiflu is critical in public health efforts during flu outbreaks and pandemics.

Tamiflu Market- Market Dynamics

Increasing prevalence of seasonal influenza worldwide and increased demand during the COVID-19 pandemic to propel market demand

Tamiflu (oseltamivir phosphate) is an antiviral medication indicated for the treatment of acute, uncomplicated influenza A and B, as well as swine flu (H1N1), in patients aged two weeks and older who have had flu symptoms for less than two days. It is available in both capsule and oral suspension forms. The market for Tamiflu (oseltamivir phosphate) is expected to grow over the forecast period, driven by the rising prevalence of seasonal influenza worldwide and increased demand during the COVID-19 pandemic, due to its relatively mild side effects. Additionally, the launch of generic versions of oseltamivir phosphate by many pharmaceutical companies is anticipated to further fuel market expansion. As Tamiflu is indicated for treating influenza A, B, and swine flu, the global rise in influenza cases is expected to boost the market. For instance, according to a November 2021 report by the World Health Organization, in 2020, there were 3 to 5 million cases of severe influenza illness globally.

Tamiflu Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.40% over the forecast period (2024-2032)

Based on Drug Type segmentation, generic was predicted to show maximum market share in the year 2023

Based on Dosage Form segmentation, capsules was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Tamiflu Market- Segmentation Analysis:

The Global Tamiflu Market is segmented on the basis of Dosage Form, Drug Type, Indication, Distribution Channel, and Region.

The market is divided into two categories based on Drug Type: branded and generic options. The generic segment is anticipated to dominate the market during the forecast period, largely driven by the high demand for oseltamivir phosphate in treating seasonal influenza. Generic versions of Tamiflu offer a more cost-effective solution, making them more accessible to a broader range of patients and healthcare systems. This affordability, coupled with comparable efficacy to branded drugs, contributes to the strong preference for generics, especially in regions with cost-sensitive healthcare models. Additionally, as many pharmaceutical companies have launched generic alternatives following the expiration of Tamiflu's patent, the market has seen increased competition, further driving down prices and boosting the availability of the drug.

The market is divided into two categories based on Dosage Form: capsules and suspension. The capsule segment is expected to lead the market throughout the forecast period due to its widespread preference for treating influenza. Capsules are convenient, easy to administer, and typically preferred by patients and healthcare providers alike for treating uncomplicated influenza cases. Furthermore, capsules offer more stability and have a longer shelf life compared to suspensions, making them more practical for stockpiling and distribution. Oral suspension, on the other hand, is generally reserved for patients who are unable to swallow capsules, such as young children or individuals with specific medical conditions. While it serves an important role in ensuring accessibility for these populations, the demand for oral suspension remains lower compared to capsules, reinforcing the latter's market dominance.

Tamiflu Market- Geographical Insights

The North America region is expected to dominate the Tamiflu market during the forecast period, primarily due to its significant market share and the increased stockpiling of Tamiflu in preparation for upcoming influenza seasons. For example, on December 21, 2022, the U.S. government announced that the U.S. Department of Health and Human Services (HHS), in collaboration with the Administration for Strategic Preparedness and Response (ASPR), is storing additional supplies of Tamiflu to meet rising demand during the 2022 flu season. This was achieved through the Strategic National Stockpile (SNS). The government, working with ASPR Regional Teams, will assess requests for Tamiflu distribution from the SNS, ensuring that states, territories, and tribes receive necessary support while maintaining preparedness for future pandemic influenza outbreaks.

Tamiflu Market- Competitive Landscape:

Companies in the Tamiflu market implement a range of strategies to improve their competitive position and increase market share. These include robust marketing campaigns aimed at educating healthcare providers and the public about flu prevention and treatment. Firms also prioritize partnerships with governments and health organizations to secure contracts for stockpiling antiviral medications during flu seasons or pandemics. Research and development efforts are important as well, with investments focused on creating next-generation antiviral therapies to combat emerging influenza strains. Further, pricing strategies are designed to align with healthcare system budgets while ensuring broad access for patients in need.

Recent Developments:

In December 2022, Genentech, Inc., U.S. biotechnology corporation, announced that Tamiflu (oseltamivir phosphate) was available for distribution across the U.S., enabling drug shipments to pharmacies nationwide.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TAMIFLU MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • F. Hoffmann-La Roche Ltd.
  • NATCO Pharma Limited
  • Teva Pharmaceutical Industries Ltd
  • LUPIN Limited
  • Amneal pharmaceuticals LLC
  • Zydus Cadila
  • Sun Pharmaceutical Industries Ltd.
  • Alembic Pharmaceuticals Limited
  • Mylan N.V.
  • Hetero Group
  • Others

GLOBAL TAMIFLU MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Capsules
  • Suspension

GLOBAL TAMIFLU MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Branded
  • Generic options

GLOBAL TAMIFLU MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Influenza A
  • Influenza B
  • Swine Flu (H1N1 Influenza A)

GLOBAL TAMIFLU MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

GLOBAL TAMIFLU MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Tamiflu Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Tamiflu Market Snippet by Dosage Form
    • 2.1.2. Tamiflu Market Snippet by Drug Type
    • 2.1.3. Tamiflu Market Snippet by Indication
    • 2.1.4. Tamiflu Market Snippet by Distribution Channel
    • 2.1.5. Tamiflu Market Snippet by Country
    • 2.1.6. Tamiflu Market Snippet by Region
  • 2.2. Competitive Insights

3. Tamiflu Key Market Trends

  • 3.1. Tamiflu Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Tamiflu Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Tamiflu Market Opportunities
  • 3.4. Tamiflu Market Future Trends

4. Tamiflu Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Tamiflu Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Tamiflu Market Landscape

  • 6.1. Tamiflu Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Tamiflu Market - By Dosage Form

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Dosage Form, 2023 & 2032 (%)
    • 7.1.2. Capsules
    • 7.1.3. Suspension

8. Tamiflu Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Branded
    • 8.1.3. Generic options

9. Tamiflu Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Influenza A
    • 9.1.3. Influenza B
    • 9.1.4. Swine Flu (H1N1 Influenza A)

10. Tamiflu Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 10.1.2. Hospital pharmacies
    • 10.1.3. Retail pharmacies
    • 10.1.4. Online pharmacies

11. Tamiflu Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Tamiflu Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Tamiflu Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Tamiflu Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Tamiflu Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Tamiflu Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Tamiflu Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. F. Hoffmann-La Roche Ltd.
    • 12.2.2. NATCO Pharma Limited
    • 12.2.3. Teva Pharmaceutical Industries Ltd
    • 12.2.4. LUPIN Limited
    • 12.2.5. Amneal pharmaceuticals LLC
    • 12.2.6. Zydus Cadila
    • 12.2.7. Sun Pharmaceutical Industries Ltd.
    • 12.2.8. Alembic Pharmaceuticals Limited
    • 12.2.9. Mylan N.V.
    • 12.2.10. Hetero Group
    • 12.2.11. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제